title: Glutamatergic medications for the treatment of drug and behavioral addictions.
abstract: Historically, most pharmacological approaches to the treatment of addictive disorders have utilized either substitution-based methods (i.e., nicotine replacement or opioid maintenance) or have targeted monoaminergic or endogenous opioidergic neurotransmitter systems. However, substantial evidence has accumulated indicating that ligands acting on glutamatergic transmission are also of potential utility in the treatment of drug addiction, as well as various behavioral addictions such as pathological gambling. The purpose of this review is to summarize the pharmacological mechanisms of action and general clinical efficacy of glutamatergic medications that are currently approved or are being investigated for approval for the treatment of addictive disorders. Medications with effects on glutamatergic transmission that will be discussed include acamprosate, N-acetylcysteine, d-cycloserine, gabapentin, lamotrigine, memantine, modafinil, and topiramate. We conclude that manipulation of glutamatergic neurotransmission is a relatively young but promising avenue for the development of improved therapeutic agents for the treatment of drug and behavioral addictions.
authors.affiliation: Department of Psychology, Arizona State University, Tempe, AZ 85287, USA. foster.olive@asu.edu
authors.forename: M Foster
authors.initials: MF
authors.lastname: Olive
authors.forename: Richard M
authors.initials: RM
authors.lastname: Cleva
authors.forename: Peter W
authors.initials: PW
authors.lastname: Kalivas
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Malcolm
mesh_terms: D000818:Animals; D018698:Glutamic Acid / Q000627:therapeutic use*; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy*; D019966:Substance-Related Disorders / Q000188:drug therapy*
chemical_list: D018698:Glutamic Acid